minutes matter in an emergency, an organized response with organ-
ized supplies can mean the difference between life and death.
When our rapidly growing healthcare system expanded to add 4
separate procedural areas where anesthesia would be administered,
we added 4 additional
MH carts. All of the
carts were stocked
according to the
Malignant
Hyperthermia
Association of the
United States
(MHAUS) resources
(osmag.net/NGGb3x).
However, each new
cart was a little bit
different than the oth-
ers. Our hospital
brought together a
team of staff from
each of the 5 clinical
areas to develop stan-
dardized carts that
would be used
throughout the health
system. Here's how
we reevaluated and
restocked each cart.
J U L Y 2 0 1 8 • O U T PA T I E N TS U R G E R Y. N E T • 2 7
Important Safety Information
The use of
The use of Revonto in the management of malignant hyperthermia crisis is not a substitute for previously
known supportive measures. These measures must be individualized, but it will usually be necessary to
discontinue the suspect triggering agents, attend to increased oxygen requirements, manage the
metabolic acidosis, institute cooling when necessary, monitor urinary output, and monitor for
electrolyte imbalance. Patients who receive i.v. dantrolene sodium preoperatively should have vital
signs monitored.
If patients judged malignant hype
If patients judged malignant hyperthermia susceptible are administered dantrolene sodium
preoperatively, anesthetic preparation must still follow a standard malignant hyperthermia susceptible
regimen, including the avoidance of known triggering agents. Monitoring for early clinical and
metabolic signs of malignant hyperthermia is indicated because attenuation of malignant
hyperthermia, rather than prevention, is possible.
Despite initial satisfacto
Despite initial satisfactory response to i.v. dantrolene there have been reports of fatality, which involve
patients who could not be weaned from dantrolene after initial treatment. The administration of i.v.
dantrolene is associated with loss of grip strength and weakness in the legs, as well as drowsiness and
dizziness. There have been reports of thrombophlebitis following administration of intravenous
dantrolene. Tissue necrosis secondary to extravasation has been reported. Injection site reactions
(pain, erythema, swelling), commonly due to extravasation, have been reported. Fatal and non-fatal
liver disorders of an idiosyncratic or hypersensitivity type may occur with dantrolene sodium therap
liver disorders of an idiosyncratic or hypersensitivity type may occur with dantrolene sodium therapy.
To report SUSPECTED ADVERSE REACTIONS contact US WorldMeds at 1-888-900-8796 or MEDWATCH at
1-800-FDA-1088 (1-800-332-1088) or http://www.FDA.gov/medwatch/.
To see the full prescribing information visit www.revonto.com.
© 2017. US WorldMeds, LLC. Revonto is a registered trademark of US WorldMeds, LLC.
REV-P91-0217
®
36
month
shelf
life*
Ready
to
administer
in
20
seconds
†
Are You Prepared for a CRISIS?
Visit www.revonto.com or call (877) 411-USWM (8796)
to learn more and to see the full Prescribing Information.
*from the date of manufacture
†
or until solution is clear
